Chart, Financials, Historical Prices, Industry, Insider, Messages, Options, Profile, Reports, Research, SEC Filings, more...

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 22-Nov-2009
New Screen 

All Reports | Brokerage Reports | Independent Reports
All Reports (Showing 1 to 10 of 56)
Release
Date
 [down]
Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
20-Nov-09Directors Deals Ltd.Company SnapshotCompany Snapshot - Perrigo Co1$10  View Abstract
20-Nov-09New Constructs, LLCN/APRGO: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings19$10  View Abstract
20-Nov-09Stock Traders DailyThomas H. Kee Jr.S&P Valuation Analysis13$50  View Abstract
20-Nov-09Ford Investor Services, Inc.N/AValue Graph: PERRIGO -- PRGO1$4  View Abstract
20-Nov-09Ford Investor Services, Inc.N/AIndustry Value Graph: CEPH , KVA , MRX , PRGO , VRX -- DRUGS3$4  View Abstract
19-Nov-09Zacks Investment Research Inc.N/APERRIGO COMPANY (PRGO) Zacks Company Snapshot1$10  View Abstract
19-Nov-09Plunkett Research, Ltd.Jack W. PlunkettBiotechnology & Genetics Industry Market Research and Competitive Analysis 2010569$299  View Abstract
19-Nov-09Plunkett Research, Ltd.Jack W. PlunkettBiotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary)71$199  View Abstract
18-Nov-09Zacks Investment Research Inc.N/APERRIGO COMPANY (PRGO) Zacks Company Snapshot1$10  View Abstract
15-Nov-09Wright ReportsN/AWright Industry Averages: Health, Medicine and Pharmaceuticals (Global)148$169  View Abstract
Next 20

Brokerage Reports (Showing 1 to 7 of 7)
Release
Date
 [down]
Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
3-Nov-09Caris & CompanyLinda Bolton WeiserPRGO-Big Cold/Flu Benefit to Come in 2Q108$25  View Abstract
2-Nov-09Collins Stewart LLCLouise ChenQuality F1Q10 Beat, Increasing Forecasts and Price Target to $4513$50  View Abstract
2-Nov-09Thomson StreetEventsN/APRGO - Event Transcript of Perrigo conference call, Nov. 02, 2009 / 10:00am ET20$75  View Abstract
2-Nov-09Thomson StreetEventsN/APRGO - Event Brief of Perrigo conference call, Nov. 02, 2009 / 10:00am ET22$75  View Abstract
19-Oct-09Collins Stewart LLCLouise ChenLaunch of Generic Duac Earlier Than Expected; Reiterating Buy3$10  View Abstract
16-Oct-09Collins Stewart LLCLouise ChenNovember 2009 Stock Catalysts22$75  View Abstract
15-Oct-09Collins Stewart LLCLouise ChenKey Takeaways From IMS Review of Worldwide Pharma Market in 20108$25  View Abstract

Independent Reports (Showing 1 to 10 of 49)
Release
Date
 [down]
Contributor Author Title Pages Price More Info
20-Nov-09Directors Deals Ltd.Company SnapshotCompany Snapshot - Perrigo Co1$10View Abstract
20-Nov-09New Constructs, LLCN/APRGO: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings19$10View Abstract
20-Nov-09Stock Traders DailyThomas H. Kee Jr.S&P Valuation Analysis13$50View Abstract
20-Nov-09Ford Investor Services, Inc.N/AValue Graph: PERRIGO -- PRGO1$4View Abstract
20-Nov-09Ford Investor Services, Inc.N/AIndustry Value Graph: CEPH , KVA , MRX , PRGO , VRX -- DRUGS3$4View Abstract
19-Nov-09Zacks Investment Research Inc.N/APERRIGO COMPANY (PRGO) Zacks Company Snapshot1$10View Abstract
19-Nov-09Plunkett Research, Ltd.Jack W. PlunkettBiotechnology & Genetics Industry Market Research and Competitive Analysis 2010569$299View Abstract
19-Nov-09Plunkett Research, Ltd.Jack W. PlunkettBiotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary)71$199View Abstract
18-Nov-09Zacks Investment Research Inc.N/APERRIGO COMPANY (PRGO) Zacks Company Snapshot1$10View Abstract
15-Nov-09Wright ReportsN/AWright Industry Averages: Health, Medicine and Pharmaceuticals (Global)148$169View Abstract
Next 20

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.


Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.